Costimulatory wars: the tumor menace

• Published in: Current Opinion in Immunology Vol. 12; no. 5; pp. 589 - 596
• Main Authors: Hurwitz, Arthur A, Kwon, Eugene D, van Elsas, Andrea
• Format: Book Review Journal Article
• Language: English
• Published: England Elsevier Ltd 01-10-2000
• Subjects: 4-1BB; AB7 antigen; Abatacept; Antigens, CD; Antigens, Differentiation - physiology; B7-1 Antigen - physiology; CD28 Antigens - physiology; CD40; CD40 antigen; CD40 Antigens - physiology; Costimulation; CTLA-4; CTLA-4 Antigen; CTLA-4 protein; Humans; ICOS; Immunoconjugates; Immunotherapy; LIGHT; Membrane Proteins - physiology; Neoplasms - therapy; OX-40; Receptors, OX40; Receptors, Tumor Necrosis Factor; T cell; Tumor Necrosis Factor Ligand Superfamily Member 14; Tumor Necrosis Factor Receptor Superfamily, Member 7 - physiology; Tumor Necrosis Factor-alpha - physiology; OX-40; CD40; Immunology; Costimulation; T cell; Immunotherapy; LIGHT; 4-1BB; Cancer Biology; CTLA-4; ICOS
• ISSN: 0952-7915; 1879-0372
• DOI: 10.1016/S0952-7915(00)00147-3

Advances in our understanding of T cell costimulatory molecules have provided a vast array of novel approaches to tumor immunotherapy. In the past year, combinatorial immunotherapy based on earlier studies of CTLA-4 blockade, the identification of novel B7-family members, the modulation of CD40 to reverse tolerance to tumor-associated antigens and the use of OX40 to enhance antitumor responses of CD4
+ T cells have all contributed to the development of more-powerful immunomodulatory cancer therapies.